New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Subscribe To Our Newsletter & Stay Updated
